Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.3%

29 terminated/withdrawn out of 143 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

24%

35 trials in Phase 3/4

Results Transparency

2%

2 of 87 completed trials have results

Key Signals

12 recruiting2 with results28 terminated

Enrollment Performance

Analytics

Phase 2
72(52.6%)
Phase 3
34(24.8%)
Phase 1
24(17.5%)
N/A
6(4.4%)
Phase 4
1(0.7%)
137Total
Phase 2(72)
Phase 3(34)
Phase 1(24)
N/A(6)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (143)

Showing 20 of 143 trials
NCT07574047Phase 4Not Yet Recruiting

MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.

Role: lead

NCT05815927Phase 3Recruiting

Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer

Role: collaborator

NCT07158489Phase 2Not Yet Recruiting

Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC

Role: lead

NCT07020065Phase 2Recruiting

Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

Role: lead

NCT06358573Phase 2Recruiting

Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK

Role: lead

NCT07365423Phase 2Recruiting

Terbinafine for Biochemically Recurrent Prostate Cancer (TerbinaPro)

Role: lead

NCT04245514Phase 2Active Not Recruiting

Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)

Role: lead

NCT06114108Not ApplicableRecruiting

Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients

Role: lead

NCT06401980Phase 2Recruiting

Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Role: lead

NCT06090162Not ApplicableActive Not Recruiting

LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma

Role: lead

NCT07149649Phase 2Not Yet Recruiting

Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)

Role: lead

NCT07237256Phase 3Recruiting

Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib

Role: collaborator

NCT05904119Phase 3Recruiting

Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study

Role: collaborator

NCT04630730Phase 2Active Not Recruiting

Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

Role: lead

NCT03937843Phase 2Active Not Recruiting

Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma

Role: lead

NCT07309497Recruiting

Pragmatic Geriatric Assessment Before CAR-T or Bispecific Antibody Therapy to Predict Side Effects and Outcomes in Older Patients (GA-ACT Trial)

Role: collaborator

NCT06452394Phase 2Recruiting

NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline

Role: lead

NCT06835049Phase 2Recruiting

Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue Sarcoma (TNT-HYPE)

Role: lead

NCT04604067Phase 2Active Not Recruiting

Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.

Role: lead

NCT02051218Phase 3Active Not Recruiting

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

Role: lead